Adjuvant therapy for renal cell carcinoma

The following articles from various urology conferences in 2018 summarise the status of research with respect to adjuvant therapy after nephrectomy for people with localised renal cell carcinoma (RCC). Many adjuvant therapies have been assessed in clinical trials, such as radiotherapy, vaccines, immunotherapy, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI), and checkpoint inhibitors. […]

read more

Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer

A recent article in Annals of Oncology reports new patient-reported outcomes data from the S-TRAC study to suggest that adjuvant sunitinib treatment in patients with a high risk of recurrence of renal cell carcinoma (RCC) was linked to increased symptoms and a worse health-related quality of life (HRQoL) compared with placebo. The S-TRAC study showed that […]

read more

Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer

According to the results of a recent meta-analysis of three phase III studies, adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) has no compelling benefit in the treatment of high-risk renal cell carcinoma (RCC). The meta-analysis was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting this week. […]

read more

Axitinib fails as an adjuvant therapy for high risk kidney cancer

The phase 3 ATLAS clinical trial to assess axitinib as an adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy has been stopped early. An interim analysis showed that it was highly unlikely that axitinib would offer any benefit for these patients. The interim analysis failed to demonstrate a […]

read more

Adjuvant sunitinib declined by European Medicines Agency committee

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended against the use of sunitinib (Sutent) as an adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). However, the CHMP’s recommendation is not binding […]

read more

Status of adjuvant therapy for the treatment of kidney cancer

Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]

read more

Pembrolizumab investigated as adjuvant therapy for renal cell carcinoma

Immunotherapy has been a major breakthrough in the treatment of renal cell carcinoma (RCC). Researchers are investigating immunotherapy drugs in various combinations with other immunotherapy agents and vascular endothelial growth factor (VEGF) inhibitors and in various settings for the treatment of this disease. Currently, the phase III KEYNOTE-564 trial is looking at pembrolizumab (Keytruda) as […]

read more

Adjuvant therapy for renal cell carcinoma

The following article is a good review of the data from recent clinical trials of adjuvant targeted therapy for renal cell carcinoma (RCC). Adjuvant therapy is the treatment received after surgery to prevent the cancer from spreading and/or returning. The success of targeted therapies, such as vascular endothelial growth factor (VEGF) inhibitors (sunitinib and pazopanib) […]

read more

Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions

The following articles discuss the use of neoadjuvant therapy (drug treatment given before surgery) and adjuvant therapy (drug treatment given after surgery) for renal cell carcinoma, including a summary of current clinical trials and future directions. Read the neoadjuvant article in UroToday here Read the adjuvant article in UroToday here

read more

Adjuvant therapy for high risk kidney cancer

Dr Umberto Capitanio from the Department of Urology, San Raffaele Scientific Institute, Milan, Italy, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases. In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to […]

read more
Showing 11 to 20 of 33 results
  TOP